WHO ICTRP trial
Paclitaxel with biweekly cetuximab for platinum- and immune checkpoint…
JPRN-jRCTs051200040 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCTs051200040 |
|---|---|
| Public title | Paclitaxel with biweekly cetuximab for platinum- and immune checkpoint inhibitor-refractory head and neck cancer |
| Scientific title | Paclitaxel with biweekly cetuximab for platinum- and immune checkpoint inhibitor-refractory head and neck cancer |
| Primary sponsor | Kiyota Naomi |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Conditions | Head and neck squamous cell carcinoma Head and neck cancer, squamous cell carcinoma;D000077195;Head and neck cancer, squamous cell carcinoma |
| Interventions | Paclitaxel + cetuximab combination therapy |
| Registration date | Jul 30, 2020 |
| Target size | 35 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: